3Q'25 vs. 3Q'24 Results Sales: € 1.635 Bn (+5.6% vs. +5.0% BS(e) and +4.7% consensus); EBITDA: € 652.7 M (+8.2% vs. +5.1% BS(e) and +4.9% consensus); 9M'25 vs. 9M'24 Results Sales: € 4.895 Bn (+6.4% vs. +6.2% BS(e) and +6.1% consensus); EBITDA: € 1.929 Bn (+6.8% vs. +5.8% BS(e) and +5.7% consensus);
3Q'25 vs. 3Q'24 Results Sales: € 9.328 Bn (0.0% vs. +2.3% BS(e) and n/a consensus); EBIT: € 2.053 Bn (+2.0% vs. +12.8% BS(e) and +4.1% consensus); 9M'25 vs. 9M'24 Results Sales: € 25.234 Bn (+4.9% vs. +5.8% BS(e) and n/a consensus); EBIT: € 5.852 Bn (+76.2% vs. +24.9% BS(e) and +19.6% consensus);
3Q'25 vs. 3Q'24 Results Sales: € 1.175 Bn (2.8% vs. 3.1% BS(e) and 1.3% consensus); EBITDA: € 371 M (27.7% vs. 23.0% BS(e) and 20.1% consensus); EBIT: € 273 M (1.2% vs. 15.2% BS(e) and 20.2% consensus); Net Profit: € 31 M (41.5% vs. 35.1% BS(e) and 70.7% consensus). 9M'25 vs. 9M'24 Results Sales: € 3.412 Bn (4.6% vs. 4.7% BS(e) and 4.0% consensus); EBITDA: € 1.018 Bn (7.4% vs. 6.0% BS(e) and 5.1% consensus); EBIT: € 737 M (-15.2% vs. -10.9% BS(e) and -9.3% consensus); Net Profit: € 62 M (-16.2%...
Rdos. 3T'25 vs 3T'24: Ventas: 9.328 M euros (0,0% vs +2,3% BS(e) y n/a consenso); EBIT: 2.053 M euros (+2,0% vs +12,8% BS(e) y +4,1% consenso). Rdos. 9meses'25 vs 9meses'24: Ventas: 25.234 M euros (+4,9% vs +5,8% BS(e) y n/a consenso); EBIT: 5.852 M euros (+76,2% vs +24,9% BS(e) y +19,6% consenso).
3Q'25 vs. 3Q'24 Results Sales: € 995.0 M (+1.3% vs. +1.2% BS(e) and +1.3% consensus); EBITDA: € 831.0 M (+2.7% vs. +2.2% BS(e) and +2.2% consensus); Net Profit: € -158.0 M (vs. € 278 M in 3Q’24); 9M'25 vs. 9M'24 Results Sales: € 2.937 Bn (+1.2% vs. +1.1% BS(e) and +1.2% consensus); EBITDA: € 2.436 Bn (+2.1% vs. +1.9% BS(e) and +1.9% consensus); Net Profit: € -263.0 M (€ -148.0 M in 9M'24 vs);
Rdos. 3T'25 vs 3T'24: Ventas: 1.635 M euros (+5,6% vs +5,0% BS(e) y +4,7% consenso); EBITDA: 652,7 M euros (+8,2% vs +5,1% BS(e) y +4,9% consenso). Rdos. 9meses'25 vs 9meses'24: Ventas: 4.895 M euros (+6,4% vs +6,2% BS(e) y +6,1% consenso); EBITDA: 1.929 M euros (+6,8% vs +5,8% BS(e) y +5,7% consenso).
Rdos. 3T'25 vs 3T'24: Ventas: 995,0 M euros (+1,3% vs +1,2% BS(e) y +1,3% consenso); EBITDA: 831,0 M euros (+2,7% vs +2,2% BS(e) y +2,2% consenso); BDI: -158,0 M euros (vs 278 M euros en 3T’24); Rdos. 9meses'25 vs 9meses'24: Ventas: 2.937 M euros (+1,2% vs +1,1% BS(e) y +1,2% consenso); EBITDA: 2.436 M euros (+2,1% vs +1,9% BS(e) y +1,9% consenso); BDI: -263,0 M euros (-148,0 M euros en 9meses'24).
Rdos. 3T'25 vs 3T'24: Ventas: 1.175 M euros (2,8% vs 3,1% BS(e) y 1,3% consenso); EBITDA: 371 M euros (27,7% vs 23,0% BS(e) y 20,1% consenso); EBIT: 273 M euros (1,2% vs 15,2% BS(e) y 20,2% consenso); BDI: 31 M euros (41,5% vs 35,1% BS(e) y 70,7% consenso). Rdos. 9M'25 vs 9M'24: Ventas: 3.412 M euros (4,6% vs 4,7% BS(e) y 4,0% consenso); EBITDA: 1.018 M euros (7,4% vs 6,0% BS(e) y 5,1% consenso); EBIT: 737 M euros (-15,2% vs -10,9% BS(e) y -9,3% consenso); BDI: 62 M euros (-16,2% vs -18,2% BS...
NEWS SUMMARY: ACS, AMADEUS, CELLNEX, IAG, SACYR. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’25 results to be released over the coming days in Spain. Doubts persist With the results campaign entering the final stretch, the main European indices closed with losses, with the IBEX standing out as the best performer, remaining at around 16,100. In the STOXX 600, Basic Mate...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACS, AMADEUS, CELLNEX, IAG, SACYR. EUROPA: BAYER. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’25 que se publicarán en España y Europa en los próximos días. Se mantienen las dudas Con la campaña de resultados entrando en su recta final, los principales índices europeos cerraron con pérdidas, destacando...
European Portfolio No changes this week. European High Yield Portfolio Air Liquide, Airbus, ASML, AXA & L’Oréal No changes this week. Spanish Recommended Portfolio No changes this week. 5-Stock Recommended Portfolio Cellnex, Ferrovial, IAG, Indra & Merlin No changes this week. 5 High-Yield Stock Portfolio Acerinox, Colonial, Iberdrola, Redeia and Santander We replace Mapfre with Santander. Mid&Small Recommended Portfolio Acerinox, Amper, CAF, CIE Automotive, Fluidra, Global Dominion, In...
Media es el peor sector del año (-16,5% vs +12,4% STOXX 600) ante la irrupción de la IA y las dificultades que plantearía para la monetización de sus servicios. También tendría sensibilidad negativa a actividad y al euro/dólar (negativo actualmente). Aunque cotiza a múltiplos atractivos, podría seguir lastrado por la IA y bajamos recomendación a Neutral. Química también acumula mala evolución este año (-6%) y estaría en niveles estresados en evolución relativa al STOXX 600 (
Cartera Modelo Europa Sin cambios esta semana. Cartera High Yield Europa Air Liquide, Airbus, ASML, AXA y L’Oréal Sin cambios esta semana. Cartera Modelo España Sale Mapfre y subimos peso en Iberdrola, Repsol, Sacyr, Colonial e Inditex. Cartera 5 Valores España Cellnex, Ferrovial, IAG, Indra y Merlin Sin cambios esta semana. Cartera 5 valores High Yield España Acerinox, Colonial, Iberdrola, Redeia y Santander Sale Mapfre y entra Santander. Cartera Pequeñas y Medianas España Acerinox, A...
3Q'25 vs. 3Q'24 Results Sales: € 210.51 M (-10.5% vs. -11.3% BS(e) and -11.0% consensus); EBITDA: € 83.9 M (-13.8% vs. -19.2% BS(e) and -15.0% consensus); EBIT: € 76.35 M (-15.3% vs. -21.0% BS(e) and -16.2% consensus); Net Profit: € 58.0 M (-16.1% vs. -18.5% BS(e) and -15.1% consensus); 9M'25 vs. 9M'24 Results Sales: € 525.1 M (-7.0% vs. -7.3% BS(e) and -7.2% consensus); EBITDA: € 149.5 M (-10.6% vs. -13.8% BS(e) and -11.3% consensus); EBIT: € 127.3 M (-13.2% vs. -16.7% BS(e) and -13.7% consensu...
4Q'25 vs. 4Q'24 Results Sales: € 448.0 M (+2.1% vs. +1.7% BS(e) and +1.1% consensus); EBIT: € 91.0 M (-4.2% vs. -4.3% BS(e)); Net Profit: € 67.0 M (-5.6% vs. -9.3% BS(e)); FY2025 vs. FY2024 Results Sales: € 1.81 Bn (+3.0% vs. +2.9% BS(e) and +2.7% consensus); EBIT: € 378.0 M (-1.8% vs. -1.8% BS(e)); Net Profit: € 281.0 M (-8.8% vs. -9.6% BS(e));
Rdos. 3T'25 vs 3T'24: Ventas: 20.128 M euros (-2,3% vs -2,8% BS(e) y -2,6% consenso); EBIT: 1.477 M euros (+7,6% vs -7,6% BS(e) y -6,7% consenso); BDI: 840,0 M euros (+11,9% vs -5,9% BS(e) y -4,7% consenso). Rdos. 9meses'25 vs 9meses'24: Ventas: 60.763 M euros (-1,2% vs -1,4% BS(e) y -1,3% consenso); EBIT: 4.276 M euros (+5,9% vs +0,7% BS(e) y +1,0% consenso); BDI: 2.441 M euros (+9,1% vs +3,1% BS(e) y +3,5% consenso).
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.